TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03064607

Intervention type: OTHER
Intervention: Fluid collection
Description: Fluids tested for biomarker S100beta
Study: NCT00834574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir for oral suspension 250 mg/5mL
Description: 1 x 250 mg/5mL, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMNICEF® for oral suspension 250 mg/5mL
Description: 1 x 250 mg/5mL, single dose fasting
Study: NCT04217317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613
Description: CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
Study: NCT02880319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Linear Accelerator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Linear Accelerator
Study: NCT05149794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic Exercises
Description: Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
Study: NCT03286088

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TransEsophageal Echocardiography and TransEsophageal Echocardiography
Description: imaging as standard practice

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TransEsophageal Echocardiography and TransEsophageal Echocardiography
Description: imaging as standard practice

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TransEsophageal Echocardiography and TransEsophageal Echocardiography
Description: imaging as standard practice

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Magnetics Resonance
Description: imaging as standard practice
Study: NCT00763282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education (ED)
Description: The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
Study: NCT00285688

Intervention type: PROCEDURE
Intervention: gastroscopic examination
Description: gastroscopic examination for tissue biopsy and real time PCR for gene study

Intervention type: PROCEDURE
Intervention: gastroscopic examination
Description: gastroscopic examination for tissue biopsy and real time PCR for gene study
Study: NCT01161719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parent training
Description: Behavioral management skill training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent training
Description: Behavioral management skill training
Study: NCT03835572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CircaHealth: a course on circadian rhythms and health
Description: Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene materials
Description: Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
Study: NCT04273061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated
Study: NCT03651544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: 1 dose (0,5 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: 1 dose (0,5 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: 1 dose (0,5 ml)
Study: NCT04273061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated
Study: NCT00684099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
Study: NCT01543958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Study: NCT02649270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1h
Description: Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
Study: NCT03286088

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MitraClip
Description: imaging as standard practice
Study: NCT02245568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMTM
Description: The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
Study: NCT02037802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-Braun, Perifix® ONE Paed, Germany
Description: caudal epidural catheterization bupivacaine fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Study: NCT01532739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
Study: NCT02037802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: fentanyl propofol atracurium besylate

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: fentanyl propofol atracurium besylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fentanyl
Study: NCT02347241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational Debriefings and High frequency training and team reflection
Study: NCT02849990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study: NCT03164109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419 IV
Description: 50mg infused IV over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infused IV over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral moxifloxacin
Description: 400 mg tablet orally with 250 mL room temperature water
Study: NCT05665517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot Little K Nurse
Description: The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed.
Study: NCT01144403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: as prescribed, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: as prescribed, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: as prescribed, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
Study: NCT01684527

Intervention type: OTHER
Intervention: Respiratory secretions obtained

Intervention type: OTHER
Intervention: Respiratory secretions obtained
Study: NCT01625507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PANDA intervention
Description: Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
Study: NCT03553563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10mg
Description: All Groups can select either capsule or sachet during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10mg
Description: All Groups can select either capsule or sachet during the study.
Study: NCT00508027

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
Study: NCT02617641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAVIEenM@RCHE
Description: The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available websites
Description: * Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)
Study: NCT04657250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation + quitline linkage text messages
Description: Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive quitline referral
Description: Single text message with contact information for the Quitline
Study: NCT00604084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin 5% lotion
Description: apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
Study: NCT03336918

Intervention type: DRUG
Intervention: Lithium
Description: Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention
Study: NCT01185379

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Efalex active 50+
Description: 4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA rich fish oil
Description: 4 x 500 mg DHA rich tuna oil to be taken daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 500 mg capsules to be taken daily for 6 months
Study: NCT02971722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml/bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml/bottle
Study: NCT02946606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: Human growth hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: Human growth hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: Human growth hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Description: Human growth hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Description: Human growth hormone
Study: NCT02649270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1h
Description: Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1h
Description: Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1h
Description: Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
Study: NCT00628056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perhexiline
Description: Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perhexiline
Description: Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
Study: NCT02849990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study: NCT03355053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O.
Study: NCT02378116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical closure of the left atrial appendage
Description: When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
Study: NCT03906734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal myectomy
Description: Transaortic septal myectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septal myectomy
Description: Transaortic septal myectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alfieri stich
Description: Transaortic Mitral valve repair using alfieri technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subvalvular intervention
Description: Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
Study: NCT03245060

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Solution Focused Brief Therapy
Description: Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
Study: NCT02946606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Description: Human growth hormone
Study: NCT02849990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT02150187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HCap Formula
Description: Pill should be taken every other day during the treatment phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar pills without active ingredients